WHO Guided Real Time Stability Testing on Shankhpushpi Syrup by Astha Jain et al.
1
Journal of Pharmaceutical 
Technology, Research and 
Management 




WHO Guided Real Time Stability Testing on 
Shankhpushpi Syrup
ASTHA JAIN, JASMEEN KAUR, NANCY, YOGITA BANSAL, BALRAJ 
SAINI AND GULSHAN BANSAL*
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, 
Patiala - 147001, Punjab, India.
*Email: gulshanbansal@rediffmail.com
Received: Dec. 02, 2016 | Revised: Feb. 03, 2017 | Accepted: March 03, 2017
Published online: May 05, 2017
The Author(s) 2017. This article is published with open access at www.chitkara.edu.
in/publications
Abstract Shankhpushpiis widely used herb in numerous CNS active 
Ayurvedic formulations, which are consumed by population of all age groups. 
The present study is designed to evaluate the stability of commercially available 
shankhpushpi syrup as per WHO guidelines. The study was conducted under 
long term conditions for 12 months on three different batches of the product. 
An HPLC-UV method was developed and validated to determine the marker 
(scopoletin) content in the stability samples. Peak purity was determined 
using HPLC-PDA analysis. Each stability sample was investigated for any 
change in physical, chemical and biological parameters with respect to control 
sample. The product was found to be stable in terms of physical parameters 
whereas significant change was observed in total phenolic content and content 
of scopoletin. The antioxidant, acetylcholine esterase inhibitory and anti-
anxiety activities of the stability samples decreased with respect to control 
sample. Moreover, there was significant variation in chemical and biological 
parameters among the batches. The findings suggested that the product was 
unstable and further studies are required to be conducted in order to determine 
the shelf life of the product.
Keywords: Stability study, Convolvulus pluricaulis, Bacopamonnieri, 
Shankhpushpi syrup, Scopoletin, HPLC-UV, HPLC-PDA
1. INTRODUCTION
CNS active herbs and herbal products contribute a significant share to herbal 








by population of all age groups without any prescription, especially in 
the developing countries, indiscriminately for varied purposes such as to 
relieve anxiety, depression and memory loss. Convolvulus pluricaulis and 
Bacopamonnieri are the most common herbs used in different CNS active 
herbal products available in market. Various drugs regulatory agencies 
such as World Health Organization (WHO), International Conference on 
Harmonization (ICH) and European Medicine Agency (EMEA) have issued 
specific guidelines for establishing shelf life of any medicinal product 
through systematic stability studies(CPMP, 2003; EMEA, 2008; EMEA 
2010; ICH, 2003; WHO, 2009). These guidelines also mention that shelf 
life recommendation should be basedon chemical stability, chromatographic 
fingerprinting and biological activity evaluation. Though some reports on 
chemical stability of C. pluricaulis and B. monnieri are available in literature 
(Phrompittayarat, W. et al, 2008;Shahare, M.D. et al, 2010; Srivastava, P. et 
al, 2010; Srivastava, P. et al, 2012), but the conditions and duration employed 
for their stability studies in these reports are not in accordance with the 
recommendations of the regulatory guidelines.
The present study reveals stability testing on three batches of a 
commercially available herbal product composed of C. pluricaulis and B. 
monnieri under long term storage condition (30°C/75%RH) as specified 
in WHO and ICHguidelines.The objective is to study any chemical and/or 
therapeutic change(s) in the formulation during storage through evaluation 
of physical, chemical and biological parameters. Each control and stability 
sample was evaluated for physicochemical stability in terms of appearance, 
pH, viscosity, total phenolic content (TPC), content of markers (scopoletin 
and bacoside A), and for different biological activities including antioxidant, 
acetylcholinesterase(AChE) inhibitory and anxiolytic activities.
2. MATERIALS AND METHODS
2.1 Materials
Three batches (A, B and C) of Shankhpusphi syrup were purchased from 
local pharmacy store. All three batches were stored under long term stability 
conditions (30±2°C/65±5%RH) and samples were withdrawn at 3, 6, 9 and 
12 months. The control samples (0 time) as well as each stability sample were 
stored at 4°C till physicochemical and biological evaluations performed.
Scopoletin, α,α-Diphenyl-β-picrylhydrazyl (DPPH), acetylthiocholine 
iodide (ATCI), acetylcholinesterase (AChE, electric eel, type VI-S lyophilized 
powder,480U/mg solid, 530U/mg protein), Bovine Serum Albumin (BSA) and 







Aldrich (Bengaluru, India). Bacoside A was purchased from Natural remedies 
(Bengaluru, India). Folin-Ciocalteu phenol reagent, methanol (HPLC grade), 
acetonitrile (HPLC grade) were obtained from Merck Specialist Pvt. Ltd. 
(Mumbai, India). Gallic acid was purchased from Hi-media Laboratories Pvt. 
Ltd.(Mumbai, India). Calmpose injection (label claim; Diazepam HCl, 10mg) 
manufactured by Ranbaxy Laboratories (Gurgaon, India) was purchased from 
local pharmacy. All other chemicals and solvents were procured from S.D. 
fine chemicals(Mumbai, India). 
2.2 Instruments
The HPLC system consisted of binary pumps (515), dual wavelength detector 
(2487) and Rheodynemanual injector (Waters, Milford, MA, USA). The data 
was acquired and processed in Empower 2 software (Waters, MA, USA). The 
chromatographic separation of the samples were achieved on Nucleodur C18 
(250×4.6mm; 5µ) and on XTerra C18 (250×4.6mm; 5µ) column. The mobile 
phase was filtered through nylon membrane (0.45µm) using Millipore filter 
assembly and was degassed using transonic sonicator bath (570/H ELMA, 
Germany). The LC-PDA analysis was carried out on Waters HPLC system 
consisting of pumps (515), auto injector (2707), and PDA detector (2998) 
(Milford, MA, USA). Samples were lyophilized using lyophilizer (Allied Frost, 
Macflow Engineering, Pvt. Ltd., New Delhi, India). UV spectrophotometer 
(DU®640 B series, Beckman, USA) was used for spectrophotometric analysis. 
The pH was measured using digital pH meter (Five Easy plus FEP 20-ATC 
kit, Mettler Toledo AG, Analytical, Schwerzenbach, Switzerland). Brookfield 
viscometer (LVDV-1 Prime viscometer, Brookfield Engineering Laboratories, 
New York, USA) was used for testing viscosity of each stability sample. Hot 
air oven equipped with digital temperature control capable of controlling 
temperature within range of ±2°C (Gupta Scientific Works, Ambala, India) 
was used for drying purposes. Stability studies were performed by using a 
stability chamber (Rolex Scientific Engineers, Ambala, India) capable of 
controlling temperature and humidity within range of ±2°C and ±5%RH, 
respectively. The chamber was set at temperature of 30°C and 65%RH.
2.3 Methods
2.3.1 Stability Studies
All three batches of the formulation were stored under long term stability 
conditions (30±2°C/65±5%RH) and samples were withdrawn at 3, 6, 9 and 
12 months. The control samples (0 time) as well as each stability sample were 









Each of the control and stability sample was evaluated for its organoleptic 
properties such as color, clarity, odor, taste, pH and viscosity. Viscosity was 
measured at 25±2°C using small volume adaptor at 20 rpm using Brookfield 
viscometerby the method as reported by Arslan, E. et al (2005). The pH and 
viscosity of each sample was recorded in triplicate. 
2.3.3 Chemical Evaluation
Total Phenolic Content
TPC was determined as grams ofgallic acid equivalent (gGAE)/L by the Folin-
Ciocalteu’s method reported by Fu, L. et al (2011) with some modifications.A 
stock solution (100µg/mL) of gallic acid in water was diluted to obtain a series 
of standard solutions of concentrations 10, 20, 30, 40, 50, 60, 70, 80, 90 and 
100µg/mL. A 0.5mL aliquot of each solution was mixed with 2.5mL of 1:10 
diluted Folin-Ciocalteu’s reagent and allowed to incubate at room temperature 
for 5min. Subsequently, 2mL of saturated sodium carbonate solution (75g/L) 
was added, mixed well and left to stand for 30min at room temperature. The 
absorbance of the resulting solution was read at 760nm taking water as blank. 
A calibration curve was constructed taking concentration of gallic acid as 
abscissa and absorbance as ordinate. The curve was constructed in triplicate 
using fresh sets of standard solutions. Each of the control and stability sample 
(diluted 1 in 32 with water) was processed similar to the standard solution of 
gallic acid to determine percent change in (gGAE)/L of each stability sample 
w.r.t. its control.
Scopoletin and Bacoside A Contents
A 5mL aliquot of each control and stability samplewas lyophilized.The 
resultant dried solid was dissolved in 10mLof methanol. 1mL of this 
solution was diluted with equal volume of methanol to obtain sample 
solution.Separate solutions of the most common excipients used for syrups 
i.e., sodium benzoate, citric acid, propyl paraben and methyl paraben 
were also prepared (0.1mg/mL) in methanol. The standard solutions of 
scopoletin and bacoside A, solutions of each control and stability sample, 
and solutions of excipients were analyzed through HPLC to determine the 
contents ofscopoletin and bacoside A in each sample. The samples were 
optimally chromatographed for determination of scopoletin on Nucleodur 
C18 (250×4.6mm; 5µ) column by isocratic elution with mobile phase 
composed of acetonitrile and phosphate buffer (20mM, pH 3.5) (20:80%v/v) 
and for determination ofbacoside A on XTerra C18 (250×4.6mm; 5µ) 







acid (35:65%v/v) flowing at a rate of 1mL/min at ambient temperature. The 
injection volume was fixed at 20µL and the eluent was detected at 205nm. 
The LC-PDA analysis of standard scopoletin solution and control samples 
of all three batches of formulation was carried out to establish purity of the 
scopoletin peak.
2.3.4 Pharmacological Activity Evaluation
Antioxidant Activity
It was evaluated as free radical scavenging activity using DPPH method as 
reported by Locatelli, M. et al (2009) with some modifications. A solution 
of DPPH (100μM, 1mg/25mL) was prepared in methanol and kept in dark at 
4°C. The stability sample (1mL) was mixed well with same volume of DPPH 
solution (100μM) and left to stand in dark at room temperature for 180min. 
Absorbance (A) of the solution was read at 515nm against methanol as blank. 
Each sample was assayed in triplicate. Anti-radical activity was expressed 
as inhibition percentage (I%) and calculated against negative control (where 
sample solution was replaced with same volume of methanol) using the 
following equation:
I% = [(Anegative control- Asample) / Anegative control] × 100
I% for control sample of each batch of the syrup was determined at different 
dilutions i.e., 1/8, 1/16, 1/32, 1/64 and 1/128 in methanol corresponding to 
concentrations of 12.5, 6.25, 3.13, 1.56 and 0.781%v/v, respectively. IC50 was 
calculated through probit regression as reported by Locatelli, M. et al (2009)
and expressed as percent concentration of the syrup (%v/v). Subsequently, the 
anti-radical activity (I%) of control and stability samples was evaluated at 
1%v/v for batch B and 2%v/v for batches A and C.
AChE Inhibitory Activity 
It was measured by the spectrophotometric method developed by Ellman, 
G.L. et al (1961)with some modifications.A mixture of 1500µL of phosphate 
buffer (0.1 M, pH 8.0), 200µL of DTNB (4mM), 100µL of stability sample 
solution and 100μL of AChE solution (0.1U/mL) was incubated for 10min 
at 25°C. The reaction was initiated by the addition of 100μL ATCI solution 
(14mM) and monitored at 405 nm. For negative control, the stability sample 
was replaced with water. All samples were analyzed in triplicate. The percent 
inhibition (I%) of AChE was calculated by formula I% = (AN – AS)/ AN× 










Swiss albino mice (20–25 g) of either sex were procured from Disease 
Free Small Animal House (ChaudharyCharan Singh Haryana Agricultural 
University, Hisar, Haryana).These were kept in animal house of Punjabi 
University, Patiala and fed with standard rodent diet and tap water ad libitum. 
Animals were exposed to natural photoperiod and were acclimatized to the 
laboratory conditions before experiments. The experimental protocol was 
duly approved by Institutional Animal Ethics Committee (IAEC) and care of 
the animals was taken as per guidelines of the Committee for the Purpose 
of Control and Supervision of Experiments on Animals (CPCSEA), Ministry 
of Environmental and Forest, Government of India, (Reg.No. 107/99/
CPCSEA-2012-24). Diazepam hydrochloride was used as a standard 
anxiolytic drug and was administered in dose of 2mg/kg i.p. Normal saline 
was used as a control.
Elevated plus maze (EPM) test: The plus maze apparatus consisting of two 
open arms measuring 16×5cm, and two closed arms measuring 16×5×12cm, 
connected to a central platform (5×5cm) was elevated to a height of 25cm 
above the floor. Each mouse was placed individually in the centre of EPM with 
its head facing toward an open arm and was observed for 5min. The behavior 
of the mouse was recorded as: (i) preference of the mouse for its first entry 
into the open or closed arms, (ii) number of entries into the open or closed 
arms, and (iii) time spent by the mouse in each of the arms (Kulkarni, S.K. et 
al,1999).Every precaution was taken to ensure that no external stimuli, other 
than height of plus maze could invoke anxiety.
Light-dark exploration test: The test apparatus consisted of a small dark 
secure compartment (one-third) and a large illuminated aversive compartment 
(two-thirds). The two compartments were connected by a small opening in 
the wall between the two compartments. An animal was placed in the centre 
of the light compartment and was observed for 5min. The apparatus was 
cleaned thoroughly between trials with damp and dry towels. The mice were 
observedfor the number of crossings between two compartments and time 
spent in the light and dark compartments. This test has the advantages of being 
quick and easy to use, without requiring the prior training of animals (Bourin, 
M. et al, 2003).
Open field exploration test: It provides simultaneous measures of locomotion, 
exploration and anxiety. The open field apparatus measured 72×72 cm with 
36 cm walls. Floor of the field was divided into sixteen (18×18 cm) squares. 
A central square was also drawn in the middle of the open field (Brown, 







spontaneous ambulatory locomotion of each mouse was quantified for 5min. 
During this period, the number of squares crossed, centre squares entries, 
time spent in centre squares and number of rearing were measured.
2.3.5 Statistical Analysis:
The data were expressed as mean ± standard error mean (SEM). The 
significance of differences among the groups was assessed using one way 
analysis of variance (ANOVA). The test was followed by Dunnett’s‘t’-test, p 
values less than 0.05 were considered as significant.
3. RESULTS AND DISCUSSION
3.1 PhysicalEvaluation
Control sample of each batch was clear, dark green in color, pleasant to 
smell and sweet to taste. All stability samples retained these organoleptic 
characters indicating no visible and perceptible change during storage for one 
year. Viscosity of control samples of the batch A, B and C was found to be 
24.80±0.02, 22.10±0.02 and 19.70±0.02cps, respectively, and only small 
negligible change was found in stability samples with time (Figure 1). ThepH 
of control sample of each batch was in the range of 4.04 to 4.20, and it changed 
insignificantly(±0.10 units) upon storage. These results indicated that there 









was no significant change in physical stability of any batch of the product after 
storage for one year under long term stability conditions.
3.2 Chemical Evaluation
Chemical stability of the products was assessed in terms of total phenolic 
content (TPC) and content of marker compounds (Scopoletin for C. pluricaulis 
and Bacoside A for B. monnieri).
3.2.1 Total Phenolic Content
TPC was determined as gram of gallic acid equivalent per litre (gGAE/L)
using Folin-Ciocalteu’s method as reported by Fu, L. et al (2011).This 
method was optimized for the present study, and found linear for gallic acid 
in the concentration range of 0.01-0.10µg/mL (y=10.236x+0.0512) with 
a correlation coefficient of 0.9992. A 1/32 diluted sample of each batch 
showed TPC within the established linearity range.Hence, control and 
stability samples of each batch were diluted 32 times to obtain working 
solutions for TPC determination. TPC of stability sampleof each of the three 
batches was found to decrease as reflected by % change in gGAE/Lwith 
time with respect to its corresponding control (Figure 2). While batches 
Figure 2: Percent change in gGAE/L of batch A, batch B and batch C with 







A and C showed 14-16% decrease, batch B showed maximum decrease 
of 25% after 12 months of storage. These findings indicate that phenolic 
compounds are unstable in the product, and their level falls with ageing of 
the product.
3.2.2 Scopoletin and Bacoside A Contents
Contents of scopoletin and bacoside A were determined by separate HPLC 
methods. Bacoside A was eluted as a characteristic set of 5 peaks within 22-40 
min(Figure 3A) whereas scopoletin was eluted at 13 min (Figure 4A).Bacoside 
A was not detected in control samples of all the three batches (Figure 3), whereas 
Figure 3: HPLC-UV chromatograms of bacosideA standard solution (A), 








scopoletin was found in control sample of each batch (Figure 4). It revealed 
that though the label claim mentioned the product to contain B. monnieri but 
actually it was absent. Presence of scopoletin in each sample was confirmed 
through matching of retention times and UV absorption spectra of scopoletin 
obtained through LC-PDA analysis. UV absorption spectrum of scopoletin 
peak in standard solution was found matching with the spectrum of peak at 13 
minin LC-UV chromatogram of each control sample (Figure 5). Out of the 
most commonly used excipients, only parabens were found in the formulations 
(Figure 4).The content of scopoletin in control samples of A and B was quite 
similar (86.41 and 95.36µg/mL) but it was very high in Batch C(158.01µg/mL) 
(Table 1).It was found to decrease with time in stability samples with respect to 
the control sample in each batch (Table 1). Further, change in scopoletin content 
in stability samples of all three batches showed a wide variability. It degraded 
by 56.52%, 59.21% and 31.42% in batches A, B and C, respectively, after 12 
months storage. It suggested that initial content of scopoletinmay have some 
Figure 4: HPLC-UV chromatograms of scopoletin standard solution (A), 








Table 1: Scopoletin content analysis of stability samples.
Product
Batch
Scopoletin content (μg/mL of syrup)a; % Change with respect to control sample

























avalues are expressed as mean±SD (n=3)
Figure 5: UV spectra of scopoletin peak in standard solution and control 








kinetic role in its degradation. Further, degradation during first three months 
was almost two times in batch B (42.53%) than in batches A and C (21.34% and 
28.31%, respectively). This variability may be attributed to different chemical 
architecture of the products. This proposition is based on the findings that LC-
UV chromatograms of control sample of batch A and C were similar but different 
from that of batch B. HPLC-UV chromatograms of representative batch A at 
five time points (0, 3, 6, 9 and 12 months) along with standard scopoletin are 
shown in Figure 6.
3.3 Pharmacological Activities
In general, no single phytoconstituent or group of constituents is held solely 
responsible for a biological activity of any plant. Therefore, assessment of 
chemical stability of herbal productin terms of a particular marker or group 
of markers may not be translated into assessment oftherapeutic efficacy of the 
product. Hence, biological activity evaluation becomes an indispensible part 
of stability evaluation program of any herbal product. As the herbal products 
containing C. pluricaulis and B. monnieri are mainly used for treatment of CNS 
related disorders, the selected products in the present study were evaluated for 
their antioxidant, anticholinesterase and anxiolytic activities.
Figure 6: HPLC-UV chromatograms of scopoletin standard solution (A), and 
of stability samples of batch A at 0 time (B), 3 month (C), 6 month (D), 9 








Antioxidant activity was determined as radical scavenging activity using 
DPPH model (Locatelli, M. et al, 2009). IC50 value of control samples of 
A, B and C was found to be 2.39±0.14, 0.94±0.05 and 1.92±0.29%v/v, 
respectively. It indicated that antioxidant activity of batches A and C was 
statistically similar but that of B was more than two times the other. Based 
on these IC50 values, antioxidant activity of batches A and C was evaluated 
at concentration of 2.0%v/v, and that of batch B was evaluated at 1.0%v/v 
concentration. It was found that antioxidant activity decreased with time in 
all three batches (Table 2). In batch A and C, the decrease was about 10% 
whereas in batch B, it was about 14%. These changes were in consonant with 
the changes in TPC (Figure 2), which suggested that antioxidant activity of 
the products might be due to phenolic compounds in the product.
3.3.2 AChE inhibitory activity
AChE inhibitory activity of control sample of each of the three batches was 
statistically different that indicates significant batch to batch variation. The 
activity of each batch was found to decrease with time (Table 2). This decrease 
was greater for batch B (-9.2%) than for batch A (-6.1%) and batch C 
(-5.32%).
3.3.3 Anxiolytic Activity 
Anxiolytic activity of each control and stability sample was evaluated using 
Elevated plus maze model (EPM) (Kulkarni, S.K., 1999), Light-Dark 
transition test (LDTT) (Bourin, M.et al, 2003)and Open field Test (OFT) 
Table 2: Antioxidant and AChE inhibitory activities of different stability 
samples.
Batch (conc.) 0 month 3 month 6 month 9 month 12 month
Antioxidant activity (I% of DPPH radical activity)a
A (2.0% v/v) 65.62 ± 0.36 59.53 ± 0.65 57.60 ± 0.75 55.53 ± 0.47 54.33 ± 0.15
B (1.0% v/v) 64.30 ± 0.85 59.77 ± 0.15 58.95 ± 0.64 50.83 ± 0.89 50.07 ± 0.74
C (2.0% v/v) 64.90 ± 0.95 62.33 ± 0.91 59.01 ± 0.92 57.28 ± 0.86 55.71 ± 0.69
AChE inhibitory activity (I% of Acetylcholinesteraseactivity)a
A 38.09 ± 0.60 36.41 ± 0.53 34.81 ± 0.66 32.17 ± 0.80 31.98 ± 0.62
B 31.66 ± 0.15 27.76 ± 0.52 25.67 ± 0.16 24.84 ± 0.28 22.46 ± 0.16
C 29.40 ± 0.13 28.18 ± 0.19 26.72 ± 0.47 25.69 ± 0.38 24.08 ± 0.27








(Brown, R.E.et al, 1999) taking diazepam hydrochloride (2mg/kg, i.p.) as 
standard drug. The dose of sample was calculated to be 5mL/kg by dose 
translation method as reported by Reagan-Shaw, S. et al(2008). Based on 
this calculated dose, each control and stability sample was administered 
orally at a dose of 0.1mL/10g body weight of mice. In EPM, antianxiety 
activity is measured in terms of number of entries and time spent by 
animals in open and closed arms. A substance increasing the permanence 
of animals in open arm (increased number of entries and time spent) is said 
to be anxiolytic. Control sampleof batch B exhibited anti-anxiety activity 
comparable to diazepam, and batches A and C showed statistically lower 
activity than diazepam (Table 3). However, this activity of the stability 
Table 3: Effect of different treatments on behavior of mice in elevated plus 
maze model.
Treatment Entries in 
open arm
Time spent 









2.00±0.36 59.33±8.18 8.50±0.43 240.67±8.18
Diazepam 6.50±0.43 101.67±5.59 5.00±0.36 198.33±5.59
Batch A
0 month 5.00±0.58b 80.33±10.32 4.67±0.33b 219.67±10.32
3 month 4.83±0.31b 72.33±8.29 4.67±0.42b 227.67±8.29
6 month 4.50±0.22b 68.67±5.44c 5.00±0.52b 231.33±5.44c
9 month 4.33±0.62b,c 68.50±7.31c 5.17±0.65b 231.50±7.31c
12 month 4.00±0.36b,c 70.00±6.59c 5.67±0.49b 230.00±6.59c
Batch B
0 month 7.17±0.70b 105.67±8.91b 5.17±0.79b 194.33±8.91b
3 month 6.50±0.76b 102.33±10.63b 6.67±0.49 197.67±10.63b
6 month 6.17±0.48b 101.67±7.70c 6.83±0.48 198.33±7.70b
9 month 6.00±0.73b 100.83±5.55b 7.17±0.87 199.17±5.55b
12 month 6.00±0.45b 98.00±6.31b 7.67±0.72c 202.00±6.31b
Batch C
0 month 4.83±0.60b 98.17±8.00b 4.33±0.42b 201.83±8.00b
3 month 4.00±0.26c 71.17±4.88c 4.83±0.31b 228.83±4.88c
6 month 3.83±0.31c 68.33±5.50c 5.17±0.40b 231.67±5.50c
9 month 3.74±0.28 66.93±6.24 5.56±0.68 233.84±6.12
12 month 3.61±0.54 63.85±5.72 5.93±0.57 235.08±7.63
Values are expressed as mean ± SEM, (n=6). Statistical analysis was done by one way ANOVA 
followed by Dunnet’s multiple comparison test; bp<0.05 compared with vehicle control group; 







samples withdrawn at 3, 6, 9 and 12 monthsof the study was decreased, 
though insignificantly, gradually with time (Table 3). It suggested that 
antianxiety activity was maximumin control sample, and it decreased 
insignificantly with time upto 12 months.
In LDTT, tendency of an animal to stay in light and dark space is studied. 
Animal having the propensity to enter the light space and stay there are said to 
be less anxious. In this test, control sample of batch B exhibited anti-anxiety 
activity comparable to diazepam whereas those of batches A and C showed the 
activity lower than diazepam (Table 4). Stability samples withdrawn at 3, 6, 
9 and 12 months showed a gradual decrease in permanence in the light space 
which suggested that antianxiety activity was maximum in control sample and 
Table 4: Effect of different treatments on behavior of mice in light-dark 
transition model.
Treatment Entries in 
light space




Time spent in dark 
space (seconds)
Control 3.00±0.36 87.67±5.70 7.17±0.31 212.33±5.70
Diazepam 5.50±0.43 138.17±9.77 3.00±0.26 161.83±9.77
Batch A 
0 month 4.83±0.48b 119.50±7.80 3.17±0.31b 180.50±7.80
3 month 4.83±0.60b 106.50±9.50 4.50±0.56b 193.50±9.50
6 month 4.67±0.67 102.17±4.64c 4.67±0.49b 197.83±4.64c
9 month 4.00±0.36 101.50±9.40c 4.67±0.33b 198.50±9.40c
12 month 3.67±0.42c 103.00±5.24c 5.33±0.49b,c 197.00±5.24c
Batch B
0 month 5.83±0.40b 135.67±10.90b 4.17±0.48b 164.33±10.90b
3 month 5.50±0.43b 131.17±9.06b 5.33±0.21b,c 168.83±9.06b
6 month 5.33±0.33b 127.17±9.58b 5.33±0.72b,c 172.83±9.58b
9 month 4.83±0.31b 124.67±8.91b 6.33±0.49c 175.33±8.91b
12 month 4.50±0.43 127.83±8.61b 6.33±0.49c 172.17±8.61b
Batch C
0 month 4.83±0.40b 109.67±6.46 5.00±0.45b,c 190.33±6.46
3 month 4.67±0.42 103.50±7.06c 5.17±0.48b,c 196.50±7.06c
6 month 4.50±0.43 101.33±6.91c 5.50±0.22c 198.67±6.91c
9 month 4.33±0.28 99.76±5.89 6.02±0.45 200.56±1.22
12 month 4.07±0.45 97.66±4.65 7.12±0.34 202.15±2.56
*Values are expressed as mean ± SEM, (n=6). Statistical analysis was done by one way ANOVA 
followed by Dunnet’s multiple comparison test; bp<0.05 compared with vehicle control group; 








it decreased, though insignificantly, with time up to 12 months. These results 
were in concordance with the results of EPM.
Open field test is used to evaluate the animal’s emotional state. It examines 
anxiety related behavior characterized by normal aversion of the animal 
to an open area. Thus, animals removed from their acclimatized cage and 
placed in open environment express anxiety and fear, by showing alteration 
in behavioral parameters. The antianxiety activity is directly related to the 
number of entries and time spent in the central square but inversely related 
to the number of rearing and number of lines crossed during 5 minute stay 
of the animal in the open field (Brown, R.E. et al, 1999). Control sample 
of batch B exhibited antianxiety activity comparable to diazepam whereas 
batches A and C showed the activity lower than diazepam (Table 5). 
Stability samples showed a gradual decrease in permanence in the centre 
square, and increase in number of rearing and number of lines crossed of the 
model, which suggested that antianxiety activity was maximum in control 
sample and it decreased, though insignificantly, with time up to 12 months 
(Table 5).
These results of antianxiety activity evaluations in all three models 
indicated that control sample of batch B showed antianxiety activity equivalent 
to diazepam, and the activity of stability samples decreased gradually with 
storage time. The 12 month stability samples of each batch showed the activity 
lower than vehicle control. It suggested that the products may not be efficacious 
in alleviating anxiety after a shelf life of 12 months. A comparative analysis of 
all findings reveals that: 
1. There is a good correspondence between percent decrease in antioxidant activity 
and in TPC in each batch after 12 months of shelf life with respect to control 
sample, which suggest that the anti-radical activity may be attributed to phenolic 
constituents in the product.
2. The extent of decrease in AChE inhibitory activity corresponds to the extent 
of decrease in antioxidant activity in each batch, which suggests that AChE 
inhibitory activity of the product may be attributed to antioxidant constituents.
3. Batch B exhibited maximum antianxiety activity whereas the best antioxidant and 
AChE inhibitory activities are exhibited by batch A. It suggests that components 
responsible for antianxiety activity may be different from those responsible for 
other activities.
4. Content of scopoletin is insignificantly different in batches A and B, and almost 
two times in batch C. These levels are found to correspond to none of the activities 
evaluated for three batches, which suggests that scopoletin may not be responsible 
for any of the activities tested. Also, it may not be a suitable marker for monitoring 








Stability testing was conducted on three batches of commercially available 
herbal formulations containing C. pluricaulis and B. monnieriunder the ICH 
recommended condition for long term stability ((30±2°C/65±5%RH). The 
samples were withdrawn at 3, 6, 9 and 12 months and were evaluated for 
physical and chemical stability and for various biological activities using 
in vitro and in vivo models. No change in the physical parameters such as 
clarity, color, odor, taste, viscosity and pH was found in any of the stability 
samples w.r.t. the control. The total phenolic content decreased with time in 
all the three batches w.r.t. the respective control. The content of scopoletin 
also decreased with time in all the batches w.r.t. the respective control as 
depicted by HPLC-UV data. It was found that more than 50% of scopoletin 
degraded in each batch just after 6 months upon storage which indicated that 
Table 5: Effect of different treatments on behavior of mice in open-field model.
Treatment Number of 
squares crossed
Rearing Centre squares 
entries
Duration in centre 
squares (seconds)
Control 93.50±2.98 34.17±1.89 1.50±0.22 2.33±0.21
Diazepam 37.67±2.28 16.17±0.98 5.50±0.34 12.00±0.89
Batch A 
0 month 49.50±3.77b 13.50±1.71b 2.33±0.33c 4.67±0.99c
3 month 50.00±1.21b 13.17±1.08b 2.17±0.31c 3.67±0.56c
6 month 50.33±4.07b 14.33±2.49b 2.33±0.21c 3.33±0.42c
9 month 56.50±4.14b,c 14.50±1.75b 2.33±0.33c 3.17±0.31c
12 month 60.17±3.88b,c 14.67±2.52b 1.83±0.31c 2.83±0.31c
Batch B
0 month 69.00±2.53b,c 15.17±0.83b 5.00±0.58b 11.83±2.34b
3 month 71.83±3.38b,c 16.50±2.38b 5.00±0.45b 9.50±2.22b
6 month 75.50±9.34c 22.33±2.43b 4.50±0.43b 8.83±2.06b
9 month 78.67±5.35c 22.67±1.67b 4.50±0.43b 6.17±1.08c
12 month 80.67±7.35c 23.00±2.39b 3.67±0.42b,c 4.67±0.76c
Batch C
0 month 41.17±4.76b 17.33±2.16b 4.83±0.95b 8.83±0.95b
3 month 44.00±3.64b 18.67±1.93b 4.50±0.34b 8.67±0.88b
6 month 54.83±2.57b 21.00±2.07b 4.00±0.36b 8.50±0.88b
9 month 56.92±3.55 23.13±1.87 3.62±0.28 7.91±0.67
12 month 57.88±2.33 24.11±1.04 3.50±0.47 7.62±0.45
*Values are expressed as mean ± SEM, (n=6). Statistical analysis was done by one way ANOVA 
followed by Dunnet’s multiple comparison test; a p<0.05 compared with vehicle control group; 








scopoletin is not very stable at long term study conditions. Comparison of 
LC-UV fingerprints of the three batches revealed that batch A and C have 
similar compositions but batch B is significantly different from the other two. 
Antioxidant activity of the three batches was found to decrease insignificantly 
and gradually up to 12 months. Acetyl cholinesterase (ACHE) inhibitory 
activity was also found to decrease in each batch, though insignificantly, with 
time. Antianxiety activity was evaluated through animal studies using three 
different models i.e., Elevated-Plus maze model, Light-Dark transition 
model and Open-field model. The results of all three models revealed that 
antianxiety activity was maximum in control (0 month) sample and decreased, 
though insignificantly, with time up to 12 months. Further, a comparison of 
all the pharmacological activities and other parameters of stability testing in 
different batches of the product revealed significant batch to batch variations. 
Thus, in the present study, changes in marker content and biological activities 
of the product during storage at long term stability conditions suggest that the 
shelf life provided on the label claim of the product do not represent its actual 
shelf life. Further studies should be conducted to establish the proper storage 
conditions and shelf life of the product.
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